Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
Histone deacetylase (HDAC) inhibitors are a class of drugs used in the cancer treatment. Here, we developed a library of 19 analogues of Vorinostat, an HDAC inhibitor used in lymphomas treatment. In Vorinostat, we replaced the hydrophobic phenyl group with various tricyclic 'caps' possessi...
Saved in:
Main Authors: | Bartosz Bieszczad (Author), Damian Garbicz (Author), Marta Świtalska (Author), Marta K. Dudek (Author), Dawid Warszycki (Author), Joanna Wietrzyk (Author), Elżbieta Grzesiuk (Author), Adam Mieczkowski (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma
by: Masumeh Sanaei, et al.
Published: (2021) -
Vorinostat-An overview
by: Aditya Kumar Bubna
Published: (2015) -
Phosphorus containing analogues of SAHA as inhibitors of HDACs
by: Michael D. Pun, et al.
Published: (2022) -
OA1-1 Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir
by: A. Capoferri, et al.
Published: (2017) -
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer
by: Subhankar Biswas, et al.
Published: (2018)